Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

Hun Ju Lee,Michael Y. Choi,Tanya Siddiqi,Jacqueline C. Barrientos,William G. Wierda,Iris Isufi,Joseph Tuscano,Nicole Lamanna,Suki Subbiah,Jean L. Koff,Lori A. Leslie,Alec Goldenberg,Gina G. Chung,James Bradley Breitmeyer,Frank J. Hsu,Michael Wang,Catriona Jamieson,Thomas J. Kipps

Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

2021

Hun Ju Lee
Michael Y. Choi
Tanya Siddiqi
Jacqueline C. Barrientos
William G. Wierda
Iris Isufi
Joseph Tuscano
Nicole Lamanna
Suki Subbiah
Jean L. Koff
Lori A. Leslie
Alec Goldenberg
Gina G. Chung
James Bradley Breitmeyer
Frank J. Hsu
Michael Wang
Catriona Jamieson
Thomas J. Kipps

7556Background: Cirmtuzumab (Cirm) is a humanized monoclonal antibody that inhibits the tumor promoting activity of ROR1 and had demonstrated additive/synergistic activity with many anti-cancer age...

Keywords:

ROR1
Ibrutinib
Medicine
Mantle cell lymphoma
Cancer research
Chronic lymphocytic leukemia
Cirmtuzumab
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations